{"id":"W2889640189","doi":"10.1200/jco.2018.36.15_suppl.tps3126","title":"An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Docetaxel; Nivolumab; Oncology; Internal medicine; Cancer; Androgen receptor; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001711269,0.002012393,0.002365577,0.0005495069,0.0006158609,0.001466555,0.001375081,0.001980744,0.008064402],"category_scores_gemma":[0.001282561,0.001118985,0.0014542,0.0004132371,0.001203673,0.001778431,0.0003926378,0.004147991,0.002106762],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001238647,"about_ca_system_score_gemma":0.002097914,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001958134,"about_ca_topic_score_gemma":0.005378348,"domain_scores_codex":[0.9995196,0.0002052957,0.00001822887,0.000112617,0.00004455117,0.00009970584],"domain_scores_gemma":[0.9991793,0.0001309264,0.0001299916,0.00006895589,0.00007320908,0.0004175628],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7334716,0.1866633,0.002224126,0.000981132,0.001154381,0.0001739233,0.0003366233,0.001880018,0.01563878,0.0002335496,0.003595425,0.05364728],"study_design_scores_gemma":[0.5636721,0.4276912,0.003775301,0.00003493129,0.0002448138,0.0001128079,0.00007516998,0.0008900017,0.001017117,0.0001780128,0.002280312,0.00002821879],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9798441,0.003105605,0.001072948,0.0006383185,0.0005388315,0.009364397,0.002197089,0.0002467649,0.002992028],"genre_scores_gemma":[0.9750954,0.002440393,0.003114862,0.001559681,0.000364812,0.008114209,0.002670444,0.00006897087,0.00657135],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008064402,"threshold_uncertainty_score":0.02697808,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2131296219286533,"score_gpt":0.551173903580684,"score_spread":0.3380442816520307,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}